Core Insights - CVS Health Corporation is recognized as one of the 13 most undervalued dividend stocks according to Wall Street analysts [1] - UBS has increased its price target for CVS from $79 to $96, maintaining a Buy rating on the stock [2] Financial Performance - In the third-quarter 2025 earnings report, CVS reported revenues of $102.8 billion, reflecting a 7.8% increase year-over-year [3] - The company generated $7.2 billion in cash flow from operations year-to-date and updated its full-year guidance to a range of $7.5 billion to $8.0 billion, an increase from the previous estimate of at least $7.5 billion [3] Dividend Information - CVS has a strong history of consistent dividend payments, having distributed regular dividends since 1997 [4] - The company currently offers a quarterly dividend of $0.665 per share, resulting in a dividend yield of 3.30% as of October 29 [4]

Core Insights - Quest Diagnostics Incorporated (DGX) is valued at a market cap of $20.5 billion and operates a comprehensive network of laboratories and services in the diagnostics industry [1][2] Company Overview - DGX is classified as a large-cap stock, emphasizing its significant size and influence in the diagnostics and research sector [2] - The company specializes in transforming diagnostic insights into actionable care through advanced technologies like digital pathology, bioinformatics, and data analytics [2] Stock Performance - Currently, DGX is trading 1.1% below its 52-week high of $185.62, with a 2.1% gain over the past three months, underperforming the Dow Jones Industrial Average's 9.8% return [3] - Over the past 52 weeks, DGX shares have surged 18.4%, outperforming the Dow Jones Industrial Average's 10.2% increase [4] - Year-to-date, DGX shares are up 21.7%, compared to the Dow Jones Industrial Average's 8.9% rise [4] Financial Performance - On July 22, DGX reported better-than-expected Q2 earnings, with net revenue growing 15.2% year-over-year to $2.8 billion, exceeding consensus estimates by 1.5% [5] - The adjusted EPS for DGX was $2.62, reflecting an 11.5% increase from the previous year and 1.9% above analyst expectations [5] - DGX raised its fiscal 2025 guidance, projecting revenue between $10.8 billion and $10.9 billion, and adjusted earnings in the range of $9.63 to $9.83 per share, indicating management's confidence in sustaining growth [5]